ADA Scientific Sessions 2025 Abstract

Prevalence and Factors for Treatment Failure with Sodium–Glucose Cotransporter 2 Inhibitor (SGLT2i) in U.S. Adults with Type 2 Diabetes (T2D)

By Xi Tan, Yiwen Cao, Yan Wang, M. Kwak

Study in peoplePopulations

The paper

Xi Tan, Yiwen Cao, Yan Wang, M. Kwak

Plainsboro

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 909-P

doi.org/10.2337/db25-909-p

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease